Carotid Stents Market Size, Share and Growth Outlook, 2026

Carotid Stents Market Snapshot: Market Size, CAGR, and Growth Outlook (2021 to 2034)

The global Carotid Stents Market size is forecast to increase from $632.79 Million in 2026 to $826.84 Million in 2034 at a CAGR of 3.4% between 2026 and 2034.

The Carotid Stents market report provides detailed analysis and outlook of Carotid Stents segments including By Product Type (Self-Expanding Stents, Balloon-Expandable Stents), By Stent Design (Drug-Eluting Carotid Stents, Bare Metal Carotid Stents, Bioabsorbable ), By Material (Metals and Alloys, Polymers and Hybrid Materials), By Procedure Type (Transfemoral Carotid Artery Stenting, Transcarotid Artery Revascularization ), By End-User (Hospitals and Surgical Suites, Specialty Cardiology and Vascular Centers, Ambulatory Surgical Centers) across global and regional markets. Further, analysis and outlook across 21 countries in North America, Europe, Asia Pacific, Middle East, Africa, and South America are provided in the study.

Carotid Stents Industry Overview

Clinical Evidence Supporting Carotid Artery Stenting in Stroke Prevention

The carotid stents industry continues to evolve as new clinical evidence strengthens the role of carotid artery stenting in the management of asymptomatic carotid stenosis. Findings from the CREST-2 study provided important insights into treatment outcomes among patients receiving carotid artery stenting combined with intensive medical management. During a four-year follow-up period, patients treated with carotid artery stenting and optimized management of blood pressure, lipid levels, and diabetes experienced a 2.8% risk of stroke or death, compared with a 6% risk among patients managed with medical therapy alone. These results highlight the potential benefits of combining advanced endovascular intervention with comprehensive cardiovascular risk reduction strategies. The growing body of evidence supporting carotid artery stenting is reinforcing its role as an important treatment option for carefully selected patients at risk of ischemic stroke, while encouraging continued refinement of procedural techniques and patient selection criteria.

Device Development and Quality Assurance Shaping Market Dynamics

The carotid stents market remains heavily influenced by ongoing product development efforts and rigorous quality management processes. InspireMD initiated a voluntary recall of its CGuard® Prime 135 cm carotid stent delivery system after identifying inconsistencies in technical performance during clinical use. Importantly, the action was limited to the delivery system and did not affect the CGuard stent implant itself, which continues to be utilized in clinical practice. The company is simultaneously pursuing regulatory approval for its original CGuard delivery system while implementing engineering enhancements for a future generation of the Prime delivery platform. This development underscores the importance of delivery system reliability in carotid artery stenting procedures, where precise deployment and device performance are critical to procedural success. Continuous product refinement and post-market surveillance remain central components of innovation and quality assurance within the carotid stent industry.

Stent Design Optimization Improving Clinical Outcomes

Advances in stent architecture are becoming increasingly important in improving patient outcomes and procedural safety within carotid artery interventions. Research published in the Journal of NeuroInterventional Surgery evaluated the comparative performance of closed-cell and open-cell carotid stent designs. Clinical findings demonstrated that closed-cell stents significantly reduced in-hospital rates of combined stroke, myocardial infarction, and death, with an incidence of 2.54% compared with 9.52% for open-cell designs. The benefits were particularly evident among high-risk patient populations, including smokers and individuals with unstable carotid plaques. These results highlight the importance of tailoring device selection to specific patient characteristics and lesion profiles. As carotid artery stenting continues to expand as a minimally invasive alternative for stroke prevention, manufacturers are increasingly focusing on optimizing stent architecture, embolic protection, and procedural performance to improve safety and long-term clinical outcomes.

Carotid Stents Market Trends, Growth Drivers, Competitive Landscape, and Future Opportunities

The global Carotid Stents market is witnessing increasing investments in innovation, product development, digital transformation, artificial intelligence integration, healthcare infrastructure expansion, and strategic partnerships across developed and emerging economies. Key Companies in the industry include- Abbott Laboratories, Boston Scientific Corporation, Medtronic plc, Terumo Corporation (Terumo Europe), Cordis (A Hellman & Friedman Company), Silk Road Medical, Inc., MicroPort Scientific Corporation, InspireMD, Inc., W. L. Gore & Associates, Inc., Balton Sp. z o.o.. The Carotid Stents market is expected to remain one of the most closely watched segments in the global healthcare industry, with companies focusing on niche market segments. As healthcare systems across the US, Europe, Asia-Pacific, Latin America, and Middle East & Africa continue to prioritize efficiency, access, and innovation, the Carotid Stents industry outlook remains shaped by rising healthcare expenditure, demographic change, digital transformation, and product innovation.
The report provides detailed market analysis including-

• Growth Carotid Stents Market size outlook across 3 scenarios- High growth, reference, and Low growth cases

• Market Trends, Drivers, Potential Opportunities, and Challenges faced by Carotid Stents companies

• Porter’s Five forces analysis- Bargaining power of buyers and sellers, Threat of Substitutes and new entrants, and Intensity of competitive rivalry

• Detailed SWOT Analysis of global and regional Carotid Stents markets

• Competitive analysis including business description, product analysis, and financial profiles

• Key country specific analysis detailing key factors shaping the short-term and long-term outlook

• Recent industry developments and news including mergers, acquisitions, product launches, expansions, and company announcements

Carotid Stents Market Competitive Benchmarking and Company Analysis

Leading companies in Carotid Stents industry include- Abbott Laboratories, Boston Scientific Corporation, Medtronic plc, Terumo Corporation (Terumo Europe), Cordis (A Hellman & Friedman Company), Silk Road Medical, Inc., MicroPort Scientific Corporation, InspireMD, Inc., W. L. Gore & Associates, Inc., Balton Sp. z o.o.. The Carotid Stents market remains moderately to highly fragmented, with competition expected to intensify as companies accelerate investments in innovation, geographic expansion, strategic partnerships, and portfolio diversification through 2034. In developed markets such as the United States, Germany, France, the United Kingdom, and Canada, competition is increasingly centered on innovation, reimbursement positioning, and value-based healthcare solutions. Meanwhile, emerging markets including China, India, Brazil, and countries across the Middle East and Africa continue to present significant opportunities for expansion due to rising healthcare expenditure, growing patient populations, and increasing access to healthcare services.

What to expect in US Carotid Stents Markets in 2026 and beyond- Market Size, Share, Growth Rate, and Forecast to 2034

The US healthcare expenditure is forecast to reach $8.2 Trillion in 2034 from $5.5 Trillion in 2026 based on the National Health Expenditure Accounts (NHEA) data. With an aging population, rising chronic disease burden, and increasing migration toward minimally invasive and outpatient care, the Carotid Stents market remains one of the strongest-performing segments in the country.
The US Carotid Stents Companies are opting new business models, optimized pricing models, industry partnerships, and AI-enabled back end transformations to enhance efficiency and cost management. The US Carotid Stents market faces successive waves of challenging trends, with strong opportunities across select segments. The CMS plan to implement Medicaid from 2027 is driving states to build eligibility verification systems throughout 2026. Looking ahead to 2034, we anticipate stronger results underpinned by opportunities exist across Carotid Stents industry. On the medical device front, over 7,000 device manufacturers continue to gain from increasing demand from demand for implantable devices, surgical instruments, monitoring equipment, and diagnostic systems.

Canada- Proximity to the US and healthcare similarities to EU5 countries fuel sales of Canadian Carotid Stents markets

Canada's strong Carotid Stents sales performance is underpinned by an aging population and a well-developed healthcare infrastructure. Steady growth in new brand spending in rural and urban locations fuel the long-term prospects of small and medium-sized enterprises across medical, diagnostic, and therapeutic devices. The Canadian Carotid Stents market presents significant opportunities for U.S. exporters of medical devices, with the U.S. being Canada’s largest trading partner for this sector. Potential advantages including specialized materials, advanced manufacturing techniques, and digital technologies support the launch of new products in the country.

Germany Carotid Stents Trends and Perspectives to 2034- Financial sustainability, hospital restructuring, demographic pressures, and digitization of care delivery continue to shape the German healthcare industry.

Germany continues to remain the largest Carotid Stents market in Europe, driven by over €600 Billion healthcare expenditure, €12 Billion medical device R&D expenditure, statutory health insurance system covering 90% German population, nationwide rollout of the electronic patient record (ePA), and large-volume of Carotid Stents population. In particular, Research and development in Germany fuels the commercialization of cutting-edge technologies. Companies across the Germany Carotid Stents industry value chain are focusing on both domestic markets and exports. The country is also driving digital adoption with the Hospital Future Act driving hospitals to upgrade their information systems by 2027. Over the forecast period, aging population, rising healthcare costs, and increasing procedural volumes drive the Carotid Stents market outlook.

France Market Size, Growth Rate, and Forecast Analysis to 2034- Universal healthcare system, high public healthcare expenditure, and strong government support Carotid Stents sales through 2034

France Carotid Stents companies are emphasizing on opportunities for rapid, at-scale innovation to boost profitability over the long-term. The country’s National Health Insurance spending target (ONDAM) estimates 3.7% growth in the country’s healthcare expenditure. Over the forecast period, expenditure control measures, chronic disease management initiatives, workforce reforms, and efforts to improve system efficiency drive the long-term prospects.
The biggest 2026 policy frame is the PLFSS 2026. The law sets the Maladie branch spending target at €271.4 billion for 2026 and fixes the ONDAM at €117.5 billion for city care, €112.8 billion for health establishments, and €18.3 billion for elderly-care establishments and services. France’s market is also being pulled by demographics. INSEE estimates that on 1 January 2026 France had 69.1 million inhabitants, with 22% aged 65 or over. INSEE also reported that 2025 births were 645,000 and deaths were 651,000, producing a negative natural balance of about 6,000 for the first time since the end of the Second World War.

UK Carotid Stents Market Size, Share, and Growth Projections to 2034- Rapid growth driven by new and existing brands across the industry value chain

Small high-need consumer segments remain key priority of Carotid Stents distributors in the UK industry. Continuous launch of new products coupled with high expenditures support the market outlook. The UK Government financing remains the dominant funding source at 81.3% of total healthcare expenditure, or £280 billion in 2025. According to the ONS, total healthcare spending grew 7.7% nominally and 3.9% in real terms from 2024 to 2025. Similarly, out-of-pocket spending was £49 billion (14.1%) and voluntary health insurance was £9.5 billion (2.8%). The market is driven by rapid digital adoption with NHS England’s plan to give more than 500,000 staff access to new AI tools.

China Carotid Stents Market Growth Drivers, Revenue Trends, and Forecast- Medical insurance coverage is rapidly expanding over the past few years

China Carotid Stents market is undergoing a structural shift from hospital-centric care toward a more integrated system emphasizing primary care, outpatient services, and long-term care. Chinese local players are emerging as a strong pillar of Carotid Stents industry, offering opportunities for both competition and partnership. Over the forecast period, new and innovative product launches remain key elements driving market outlook. China's healthcare industry is increasingly centered on expanding healthcare capacity, improving access to advanced treatments, and reducing dependence on imported technologies.
The National Healthcare Security Administration reported that by end-2024, China’s basic medical insurance covered 1.32662 billion people and the coverage rate was 95%. Regional disparities in consumer spending trends continue to become more pronounced in the Chinese Carotid Stents industry. Over the forecast period, demand will keep shifting toward geriatrics, chronic disease management, rehabilitation, long-term care, and outpatient care, while pricing pressure will remain intense in drugs and consumables because reimbursement.

India Carotid Stents Market Landscape: Current Size and Long-Term Growth Outlook - Increased pricing pressures in US market is encouraging domestic vendors to expand across India

Indian Carotid Stents market is witnessing the rapid emergence of an ecosystem that brings together diverse companies across the industry value chain. Further, large-scale healthcare public and private investments and a steady growth in chronic conditions is driving sales of pharmaceuticals and medical devices. Further, non-retail channel is experiencing volume decrease and patients are migrating to the retail. Indian medical device firms are also combining precision engineering with lower labor costs to make world-class diagnostics, robotics, and critical care devices.

Brazil Carotid Stents market remains price-driven, with products domestically manufactured and accessibility offering potential opportunities

Healthcare expenditure in Brazil exceeds 10% of GDP, with the country among the highest healthcare spenders in Latin America. ANS reported 53.2 million medical-plan beneficiaries in December 2025, while IBGE projects a steady rise in older-age cohorts, with people aged 60+ already representing about 23% of the population. The price sensitive market access is broad through the public system, private coverage adds a sizeable premium layer, and reimbursement, procurement, and hospital efficiency remain key buying drivers.

Middle East and Africa Carotid Stents Industry Trends and Perspectives to 2034

According to the World Bank, the Middle East and North Africa population exceeds 500 million, while Sub-Saharan Africa's population exceeds 1.2 billion, making the broader MEA region one of the fastest-growing healthcare demand centers globally. The GCC countries including Saudi Arabia, United Arab Emirates, Qatar, and Kuwait continue to account for a disproportionately large share of regional healthcare spending. Government-led programs such as Saudi Arabia's Vision 2030 are accelerating investments in hospital infrastructure, private-sector participation, medical technology adoption, and healthcare digitalization. On the other hand, South Africa, Egypt, Nigeria, and Kenya remain key healthcare markets due to their large populations, expanding private healthcare sectors, and growing investments in healthcare delivery systems.

Carotid Stents Market Segmentation

By Product Type
Self-Expanding Stents
Balloon-Expandable Stents
By Stent Design
Drug-Eluting Carotid Stents
Bare Metal Carotid Stents
Bioabsorbable
By Material
Metals and Alloys
Polymers and Hybrid Materials
By Procedure Type
Transfemoral Carotid Artery Stenting
Transcarotid Artery Revascularization
By End-User
Hospitals and Surgical Suites
Specialty Cardiology and Vascular Centers
Ambulatory Surgical Centers

Top Companies in Carotid Stents Industry

Abbott Laboratories
Boston Scientific Corporation
Medtronic plc
Terumo Corporation (Terumo Europe)
Cordis (A Hellman & Friedman Company)
Silk Road Medical, Inc.
MicroPort Scientific Corporation
InspireMD, Inc.
W. L. Gore & Associates, Inc.
Balton Sp. z o.o.

Countries Included

• North America- US, Canada, Mexico

• Europe- Germany, France, UK, Spain, Italy, Nordics, Others

• Asia Pacific- China, India, Japan, South Korea, Australia, Southeast Asia, Others

• Latin America- Brazil, Argentina, Others

• Middle East and Africa- Saudi Arabia, UAE, Other Middle East, South Africa, Other Africa

Latest Market Updates In Healthcare

Support this report with fresh, same-industry updates that strengthen topical depth and internal linking.

Market Update

Low MOQ, High-Mix Production Models for Indie & DTC Brands

The rising geopolitical and tariff-related uncertainties, in particular, amidst United States’ renewed protectionist trade stance continues to driv...

June 2025